Valuation: Celldex Therapeutics, Inc.

Market Cap 326.21Cr 283.09Cr 265.08Cr 242.48Cr 457.77Cr 31TCr 463.74Cr 3.1TCr 1.22TCr 16TCr 1.22TCr 1.2TCr 52TCr P/E 2026 *
-10x
P/E 2027 * -9.69x
Enterprise Value 268.07Cr 232.63Cr 217.83Cr 199.26Cr 376.17Cr 26TCr 381.08Cr 2.55TCr 1TCr 13TCr 1.01TCr 984.61Cr 42TCr EV / Sales 2026 *
1,073x
EV / Sales 2027 * 287x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celldex Therapeutics, Inc.

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 326.21Cr
+1.32%+2.06%+4.37%+17.05% 4.87TCr
-0.66%+5.09%+463.88%+564.90% 4.21TCr
+1.56%+0.34%+31.79%+7.54% 3.83TCr
+4.79%+9.65%+16.16%+84.78% 3.75TCr
+2.21%+4.89%+17.24%+51.64% 3.14TCr
+1.35%+4.01% - - 1.65TCr
+0.50%+2.20%+37.55%+126.51% 1.63TCr
-0.11%+2.41%+6.24%+18.87% 1.4TCr
-0.57%+13.98%+76.94%+29.10% 1.27TCr
Average +1.16%+3.06%+81.77%+112.55% 2.86TCr
Weighted average by Cap. +1.44%+2.31%+98.62%+134.38%

Financials

2026 *2027 *
Net sales 24.98L 21.68L 20.3L 18.57L 35.06L 24Cr 35.51L 2.37Cr 93.2L 12Cr 93.8L 91.76L 40Cr 95.14L 82.56L 77.31L 70.72L 1.34Cr 91Cr 1.35Cr 9.04Cr 3.55Cr 45Cr 3.57Cr 3.49Cr 150.71Cr
Net income -32Cr -28Cr -26Cr -24Cr -45Cr -3.05TCr -46Cr -304.41Cr -119.47Cr -1.52TCr -120.23Cr -117.62Cr -5.07TCr -36Cr -32Cr -30Cr -27Cr -51Cr -3.47TCr -52Cr -346.67Cr -136.05Cr -1.74TCr -136.92Cr -133.94Cr -5.78TCr
Net Debt -58Cr -50Cr -47Cr -43Cr -82Cr -5.54TCr -83Cr -552.77Cr -216.93Cr -2.77TCr -218.32Cr -213.57Cr -9.21TCr -53Cr -46Cr -43Cr -39Cr -74Cr -5.02TCr -75Cr -500.98Cr -196.61Cr -2.51TCr -197.86Cr -193.56Cr -8.35TCr
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
41.56USD
Average target price
57.80USD
Spread / Average Target
+39.08%

Quarterly revenue - Rate of surprise